April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Long-Term Drug-Free Remission and Visual Outcomes in Sympathetic Ophthalmia
Author Affiliations & Notes
  • Abhishek R Payal
    Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA
    Massachusetts Eye Research and Surgery Institution, Cambridge, MA
  • C Stephen Foster
    Massachusetts Eye Research and Surgery Institution, Cambridge, MA
    Harvard Medical School, Boston, MA
  • Footnotes
    Commercial Relationships Abhishek Payal, None; C Stephen Foster, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2515. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Abhishek R Payal, C Stephen Foster; Long-Term Drug-Free Remission and Visual Outcomes in Sympathetic Ophthalmia. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2515.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Sympathetic ophthalmia (SO) has an unpredictable but often chronic course requiring prolonged corticosteroid or immunosuppressive therapy (IST) or a combination of both. The therapy itself may result in additional complications in the remaining good eye. We assessed corticosteroid and IST free long-term remission in the treatment of patients with sympathetic ophthalmia.

Methods: Retrospective case series of 19 patients with sympathetic ophthalmia treated with corticosteroids and immunosuppressive therapy with a step-ladder protocol practiced at this center between March 2005-October 2013. Primary outcomes were five-year and two-year remission rates with and without corticosteroids and immunosuppressive therapy; and visual acuity.

Results: Nineteen patients (10 females, 9 males) with sympathetic ophthalmia, meeting inclusion criteria were identified for review. Patients were in the age range of 16.1-94.95 years (median age 58.56 years). Median follow-up was 7.10 years (mean, 6.41; range, 2.5 to 8.63 years). All patients achieved remission, thirteen of them for 2 years or more. Three (15.78%) of the 19 patients maintained remission off all immunosuppressive therapy and corticosteroids for more than 5 years with vision of 20/25 or better in the sympathizing eye. Thirteen patients (68.42%) were in remission on immunosuppressive therapy or corticosteroids or in combination therapy. Eleven patients (57.9%) maintained visual acuity of 20/40 or better at the end of follow up.

Conclusions: Even with a devastating and possibly lifelong disease like sympathetic ophthalmia, long-term remission off all immunosuppressive therapy and corticosteroids, perhaps even cure, is possible. It is worthwhile to consider immunosuppressive therapy early in the management of sympathetic ophthalmia for better outcomes. Studies with longer follow-up might provide additional evidence to support this.

Keywords: 746 uveitis-clinical/animal model • 432 autoimmune disease • 555 immunomodulation/immunoregulation  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.